THRB: Thyroid hormone receptor beta
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Nuclear hormone receptor that can act as a repressor or activator of transcription.
- Drugs that act on it: 3
- Approved: 1
- In phases 1 to 3: 2
- Sponsors: 3
Who Is On It, and How Far Along
Every drug ChEMBL records acting on THRB, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Thyroid hormone receptor beta-1 agonist.| Resmetirom | Approved | Madrigal Pharmaceuticals | Small molecule | Agonist | — | 12 | — |
| Eprotirome | Phase 3 | Karo Bio AB | Small molecule | Agonist | — | 0 | — |
| MB07811 | Phase 2 | Viking Therapeutics, Inc. | Small molecule | Agonist | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.| Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy | Resmetirom | — | Not yet recruiting | Radnet Management, Inc. | 2026-10-06 |
| Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis | Resmetirom | Phase 4 | Recruiting | Madrigal Pharmaceuticals, Inc. | 2026-09-29 |
| Resmetirom in Patients With MASH and HFpEF | Resmetirom | Phase 1 | Recruiting | Madrigal Pharmaceuticals, Inc. | 2026-09-21 |
| Study of Resmetirom in Children and Adolescents With MASH | Resmetirom | Phase 2 | Recruiting | Madrigal Pharmaceuticals, Inc. | 2026-08-13 |
| Nutrition Intervention Combined With Resmetirom for MASH | Resmetirom | Phase 4 | Not yet recruiting | City University of New York | 2026-07-02 |
| Rezdiffra Pregnancy and Lactation Registry | Resmetirom | — | Recruiting | Madrigal Pharmaceuticals, Inc. | 2026-04-21 |
| Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH | Resmetirom | Phase 2 | Recruiting | Madrigal Pharmaceuticals, Inc. | 2026-01-13 |
| Resmiterom Efficacy & Safety in Patients With MASH | Resmetirom | Phase 4 | Recruiting | Nabiqasim Industries (Pvt) Ltd | 2025-11-25 |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Selective pituitary resistance to thyroid hormone
- 0.78
- Generalized resistance to thyroid hormone
- 0.77
- Thyroid hormone resistance, generalized, autosomal dominant
- 0.71
- Glycogen storage disease due to glycogen branching enzyme deficiency
- 0.69
- Thyroid hormone resistance, generalized, autosomal recessive
- 0.66
- Hypothyroidism
- 0.61
- Non-alcoholic fatty liver
- 0.53
- Differentiated thyroid carcinoma
- 0.53
- Hyperthyroidism
- 0.53
- Thyroid hormone resistance syndrome
- 0.51
- Obesity disorder
- 0.48
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- THRB
- Related
- Thyroid hormone receptor
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1947, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P10828, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets